Intranasal Psychedelics Platform Is Here, Check Out Mindset's New Development

In the process of creating optimized next-generation psychedelic medicines for neurological and psychiatric disorders, drug discovery and development company Mindset Pharma Inc. MSSTF has developed a novel, patent-pending, intranasal program formulation technology expected to deliver improved central nervous system (CNS) penetration of psychedelic medicines.

Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process for psilocybin synthesizing, in addition to its own proprietary compounds. The company filed a patent application for its new development last month, with a priority date of May 26, 2021.

The novel intranasal formulation technology alters the pharmacokinetic profile of the active pharmaceutical ingredient. The evidence shows an improved CNS penetration compared to standard formulations of 5-MeO-DMT. 

Moreover, the unique formulation technology has the potential of reducing dose level and peripheral side-effects, as well as speeding uptake and out-take from the brain, all of which would enable a more efficient, safer, and more cost-effective treatment.

The company’s CEO, James Lanthier, further detailed: “The intranasal formulation technology further enhances Mindset’s portfolio of complementary scientific assets. Now, the Company has a leading portfolio of next generation NCEs (new chemical entities), patent pending processes to synthesize first generation compounds efficiently and cost-effectively, and a novel intranasal delivery system to improve the overall pharmacokinetic properties of first- and second-generation psychedelic drug candidates.” 

Mindset expects to broaden validation data as it anticipates the technological advancement will be interchangeable with other known and novel psychedelic and CNS therapeutics, besides the first-generation 5-MeO-DMT. 

Photo Courtesy of Kai Dahms on Unsplash.

Posted In: Drug DiscoveryJames Lanthierpharmacokineticspsychedelic medicinesCannabisNewsPenny StocksPsychedelicsMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.